-
The list of long-term health problems affecting patients after recovering from COVID-19 continues growing. One of these lesser-known conditions is postural orthostatic tachycardia syndrome (POTS). Although treatments for POTS exist, the condition often is missed or misdiagnosed, leading to unnecessary suffering and anxiety for patients. However, given the condition’s recent visibility, frontline providers could gain a new understanding of POTS while also providing patients with a fast, accurate explanation for their symptoms.
-
While it may be hard to understand why a person at higher risk for contracting the virus might take issue with this requirement, the idea of mandating the vaccine as a condition of employment is simply too strong a push for some. However, a coalition of healthcare organizations is calling on all medical facilities to mandate the vaccines.
-
Some emergency providers may view COVID-19 vaccinations as another task piled on an already-full plate. However, EDs are uniquely positioned to reach many underserved and high-risk populations that have yet to receive protection from COVID-19.
-
Groups call for action as cases and hospitalizations surge again.
-
Long COVID is the latest entry into a long list of potentially chronic, pandemic-associated infections. For many long COVID patients, some symptoms may be the result of a reactivation of an Epstein-Barr infection.
-
Disparate public health messaging from political officials, news media, and online outlets has occurred throughout the COVID-19 pandemic in the United States. Some have wanted to ascribe lower rates of compliance with public health guidance to political affiliation.
-
Researchers found many survivors of COVID-19 exhibited significant loss of health six months after their acute illness, with greater risk associated with severity of the acute infection.
-
Right after the FDA issued an emergency use authorization for one drug, feds pressed pause on distributing another.
-
The WHO Solidarity Trial Consortium found remdesivir, hydroxychloroquine, lopinavir, and interferon regimens produced “little or no effect” on relevant outcomes.
-
Plaintiffs expected to challenge ruling in ongoing saga over Houston facility’s policy.